These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 11249518)

  • 1. The evolving pharmacotherapeutic profile of brimonidine, an alpha 2-adrenergic agonist, after four years of continuous use.
    Cantor LB
    Expert Opin Pharmacother; 2000 May; 1(4):815-34. PubMed ID: 11249518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ongoing clinical assessment of the safety profile and efficacy of brimonidine compared with timolol: year-three results. Brimonidine Study Group II.
    Melamed S; David R
    Clin Ther; 2000 Jan; 22(1):103-11. PubMed ID: 10688394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2.
    LeBlanc RP
    Ophthalmology; 1998 Oct; 105(10):1960-7. PubMed ID: 9787370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol. Brimonidine Study Groups 1 and 2.
    Schuman JS
    Ophthalmology; 2000 Jun; 107(6):1171-7. PubMed ID: 10857839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension.
    Reis R; Queiroz CF; Santos LC; Avila MP; Magacho L
    Clin Ther; 2006 Apr; 28(4):552-9. PubMed ID: 16750466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group.
    Schuman JS; Horwitz B; Choplin NT; David R; Albracht D; Chen K
    Arch Ophthalmol; 1997 Jul; 115(7):847-52. PubMed ID: 9230823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension.
    Craven ER; Walters TR; Williams R; Chou C; Cheetham JK; Schiffman R;
    J Ocul Pharmacol Ther; 2005 Aug; 21(4):337-48. PubMed ID: 16117698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical success and quality of life with brimonidine 0.2% or timolol 0.5% used twice daily in glaucoma or ocular t hypertension: a randomized clinical trial. Brimonidine Outcomes Study Group I.
    Javitt JC; Schiffman RM
    J Glaucoma; 2000 Jun; 9(3):224-34. PubMed ID: 10877373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Brimonidine Study Group.
    Katz LJ
    Am J Ophthalmol; 1999 Jan; 127(1):20-6. PubMed ID: 9932994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brimonidine (Alphagan): a clinical profile four years after launch.
    David R
    Eur J Ophthalmol; 2001; 11 Suppl 2():S72-7. PubMed ID: 11592536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brimonidine. A review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension.
    Adkins JC; Balfour JA
    Drugs Aging; 1998 Mar; 12(3):225-41. PubMed ID: 9534022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension.
    Katz LJ
    J Glaucoma; 2002 Apr; 11(2):119-26. PubMed ID: 11912359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alpha-2 adrenergic receptor agonists are neuroprotective in experimental models of glaucoma.
    Wheeler LA; Woldemussie E
    Eur J Ophthalmol; 2001; 11 Suppl 2():S30-5. PubMed ID: 11592528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and safety of brimonidine 0.2% compared with timolol 0.5% in glaucoma: a randomized clinical trial on Taiwanese patients.
    Chen MJ; Chou JC; Hsu WM; Liu JH
    J Chin Med Assoc; 2003 May; 66(5):276-81. PubMed ID: 12908569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension.
    Goñi FJ;
    Eur J Ophthalmol; 2005; 15(5):581-90. PubMed ID: 16167288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brimonidine tartrate for the treatment of glaucoma.
    Oh DJ; Chen JL; Vajaranant TS; Dikopf MS
    Expert Opin Pharmacother; 2019 Jan; 20(1):115-122. PubMed ID: 30407890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topical brimonidine 0.2%/timolol 0.5% ophthalmic solution: in glaucoma and ocular hypertension.
    Frampton JE
    Drugs Aging; 2006; 23(9):753-61. PubMed ID: 17020399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brimonidine: a new alpha2-adrenoreceptor agonist for glaucoma treatment.
    Greenfield DS; Liebmann JM; Ritch R
    J Glaucoma; 1997 Aug; 6(4):250-8. PubMed ID: 9264305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of alpha-2 agonists in neuroprotection.
    Wheeler L; WoldeMussie E; Lai R
    Surv Ophthalmol; 2003 Apr; 48 Suppl 1():S47-51. PubMed ID: 12852434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 3-month comparison of efficacy and safety of brimonidine-purite 0.15% and brimonidine 0.2% in patients with glaucoma or ocular hypertension.
    Mundorf T; Williams R; Whitcup S; Felix C; Batoosingh A
    J Ocul Pharmacol Ther; 2003 Feb; 19(1):37-44. PubMed ID: 12648302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.